A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment

Samuel D. Capouch, Martin R. Farlow, Jared R. Brosch

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

Dementia with Lewy bodies is one of the most common causes of dementia. It is not as common as Alzheimer’s disease; the general public's awareness of the disease is poor in comparison. Its effects on caregivers and patients alike are not well known to the general population. There are currently no FDA-approved medications specifically for the treatment of DLB. Many of the medications that are approved for Alzheimer’s disease are widely used in the treatment of DLB with varying degrees of success. Treatment of DLB is life long and requires a dedicated team of physicians and caregivers to minimize the degree of morbidity and mortality experienced by the patients suffering from the disease as it progresses.

Original languageEnglish (US)
Pages (from-to)249-263
Number of pages15
JournalNeurology and Therapy
Volume7
Issue number2
DOIs
StatePublished - Dec 1 2018

Keywords

  • Alpha-synuclein
  • Dementia
  • Dementia with Lewy bodies
  • Lewy body dementia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment'. Together they form a unique fingerprint.

  • Cite this